Linvoseltamab

Phase 3

Regeneron Pharmaceuticals, Inc. (REGN)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

REGNPhase 2$57.3B

Linvoseltamab Phase 2 Est. Readout

Linvoseltamab• Monoclonal Gammopathy of Undetermined Significance (MGUS)150

Q3 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in Monoclonal Gammopathy of Undetermined Significance (MGUS)

View Full Landscape

Drug Information

Target Indication

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Clinical Trial

NCT06140524

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

REGN

Regeneron Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

AlirocumabPhase 3

Homozygous Familial Hypercholesterolemia

StatinPhase 3

Hypercholesterolemia

Intravitreal Aflibercept Injection (IAI)Phase 3

Neovascular Age-Related Macular Degeneration

LibtayoPhase 3

Non-Small Cell Lung Cancer

REGN5715Phase 3

Allergic Conjunctivitis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts